<DOC>
	<DOCNO>NCT02911935</DOCNO>
	<brief_summary>The main objective APW-RSV II clinical trial evaluate addition azithromycin routine bronchiolitis care , among infant hospitalize RSV bronchiolitis , reduce occurrence recurrent wheeze preschool year .</brief_summary>
	<brief_title>Azithromycin Prevent Wheezing Following Severe RSV Bronchiolitis-II</brief_title>
	<detailed_description>The APW-RSV II clinical trial double blind , placebo-controlled , parallel-group , randomized trial , include otherwise healthy 188 participant , age 1-18 month , hospitalize due RSV bronchiolitis . The study include active treatment phase azithromycin placebo 2 week , observational phase 48 month . The main objective APW-RSV II clinical trial evaluate addition azithromycin routine bronchiolitis care , among infant hospitalize RSV bronchiolitis , reduce occurrence recurrent wheeze ( RW ) preschool year . Study participant enrol 3 consecutive RSV season begin Fall 2016 . Study participant randomize receive PO azithromycin 10 mg/kg/day 7 day follow 5mg/kg/day additional 7 day , match placebo . The primary clinical outcome time occurrence third episode wheezing . The duration follow 18-48 month , determine base year participant recruit : first year recruit follow 48 month , 3rd year recruit follow least 18 month .</detailed_description>
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Respiratory Sounds</mesh_term>
	<criteria>Age : 118 month . Hospitalization first episode RSV bronchiolitis . Confirmed RSV infection positive nasal swab result ( PCR assay and/or direct antigen detection ) . At least two follow symptoms/signs bronchiolitis : respiratory rate great 40 breaths/minute ; cough ; wheeze ; audible rale , crackle , and/or rhonchus ; paradoxical chest movement ( retraction ) 28 . Duration respiratory symptom onset symptom current illness admission 120 hour ( 5 day ) less . Randomization perform within 168 hour ( 7 day ) onset symptom . Willingness provide informed consent child 's parent guardian . Prematurity ( gestational age &lt; 36 week ) . Presence history significant disease ( CNS , lung , cardiac , renal , GI , hepatic disease , hematologic , endocrine immune disease ) . Children atopic dermatitis and/or food allergy exclude study . Clinically significant gastroesophageal reflux currently treat daily antireflux medication ( anti H2 PPI ) . The child significant developmental delay/failure thrive , define weight &lt; 3 % age gender . History previous ( current episode ) wheeze previous ( current episode ) treatment albuterol . History previous treatment corticosteroid ( systemic inhale ) respiratory issue . Treatment ( past present ) montelukast . Treatment macrolide antibiotic ( azithromycin , clarithromycin erythromycin ) past 4 week current treatment macrolide antibiotic . Current prior treatment nonmacrolide antibiotic exclusion criterion . Chronic treatment daily medication vitamin nutritional supplement . Although routine vitamin D supplement ( 400 IU per day ) exclusion criterion , high dose vitamin D supplement allow . Participation another clinical trial . Participant require invasive mechanical ventilation due RSV bronchiolitis . Evidence family may unreliable nonadherent , definitive plan move clinical center area trial completion . Contraindication use azithromycin macrolide antibiotic history allergic reaction ( adverse reaction ) antibiotic . Diagnosis asthma . Treatment medication may cause QT interval prolongation .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>